Methotrexate in the treatment of inflammatory bowel disease: An 8-year retrospective study in a Canadian pediatric IBD center

Abstract

The long-term remission rate with MTX in our pediatric IBD population was low. However, MTX was generally well tolerated and induced and maintained remission in some patients who previously had failed a purine analog and/or anti-TNF. Prospective controlled trials are indicated to determine the place of MTX in the management of pediatric IBD.

Efficacy of oral methotrexate in paediatric Crohn’s disease: a multicentre propensity score study

“…Some of the data were used in previous publications, unrelated to the aim of this manuscript 4 8. The choice of oral or subcutaneous administration and dosing were dictated by the physicians’ discretion and centre preference.…”

Absorption of Codonopsis pilosula Saponins by Coexisting Polysaccharides Alleviates Gut Microbial Dysbiosis with Dextran Sulfate Sodium-Induced Colitis in Model Mice

“…Currently, IBD is also common in developing countries, such as countries in Asia and South America, including Brazil, South Korea, and China [8, 9], with high prevalence and rapidly increasing incidence rates. IBD commonly affects young people as a chronic disorder [1] and is conventionally treated with aminosalicylic acids [10, 11], corticosteroids [12], immune suppressants [13, 14], antibiotics [15], and biologic agents [16]. However, these agents are expensive and do not completely prevent colitis.…”

A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT)

“…nausea), liver function abnormalities and bone‐marrow suppression are the main potential side‐effects. However, based on both paediatric dermatology and rheumatology experience, MTX appears to be generally well tolerated and safe in children, even in settings where higher doses are used, often for prolonged time periods and in combination with biologics . In TREAT, safety bloods are taken 1 week after the MTX test dose to capture rare idiosyncratic reactions.…”